NCT07108985 - Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 1, 2029

Study Completion Date

August 31, 2030

Conditions

Diabetes Mellitus, Type 2HyperglycemiaInsulin Resistance

Interventions

DRUG

Sitagliptin 100 mg

Sitagliptin 100 mg, taken once daily for 24 weeks.

DRUG

Sitagliptin 100 mg + Dapagliflozin 10 mg

Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.

DRUG

Sitagliptin 100 mg + Dapagliflozin 10 mg

Sitagliptin 100 mg + Dapagliflozin 10 mg, taken once daily for 24 weeks.

DRUG

Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg

Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg, taken once daily for 24 weeks.

Trial Locations (1)

Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea, Seoul

All Listed Sponsors

lead

Yonsei University

OTHER